Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension
NCT ID: NCT01152567
Last Updated: 2011-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50000 participants
OBSERVATIONAL
2010-06-30
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACE
Patients treated for hypertension with ACEs without CVD
No interventions assigned to this group
Candesartan
Patients treated for hypertension with candesartan without CVD
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Ongoing malignancy
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Niklas Lindarck
Role: STUDY_DIRECTOR
AstraZeneca Nordic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Avesta, , Sweden
Research Site
Älvdalen, , Sweden
Research Site
Ängelholm, , Sweden
Research Site
Åkersberga, , Sweden
Research Site
Bengtsfors, , Sweden
Research Site
Borlänge, , Sweden
Research Site
Falun, , Sweden
Research Site
Farsta, , Sweden
Research Site
Fritsla, , Sweden
Research Site
Gagnef, , Sweden
Research Site
Gävle, , Sweden
Research Site
Gothenburg, , Sweden
Research Site
Grängesberg, , Sweden
Research Site
Grycksbo, , Sweden
Research Site
Hallstahammar, , Sweden
Research Site
Hägersten, , Sweden
Research Site
Hässelby, , Sweden
Research Site
Hedemora, , Sweden
Research Site
Helsingborg, , Sweden
Research Site
Henån, , Sweden
Research Site
Höllviken, , Sweden
Research Site
Jarfalla, , Sweden
Research Site
Kil, , Sweden
Research Site
Kolbäck, , Sweden
Research Site
Kolsva, , Sweden
Research Site
Köping, , Sweden
Research Site
Leksand, , Sweden
Research Site
Lidköping, , Sweden
Research Site
Likenäs, , Sweden
Research Site
Limhamn, , Sweden
Research Site
Ludvika, , Sweden
Research Site
Malmo, , Sweden
Research Site
Malung, , Sweden
Research Site
Mora, , Sweden
Research Site
Munka-Ljungby, , Sweden
Research Site
Norberg, , Sweden
Research Site
Sala, , Sweden
Research Site
Säter, , Sweden
Research Site
Skanör, , Sweden
Research Site
Skepplanda, , Sweden
Research Site
Skinnskatteberg, , Sweden
Research Site
Skogås, , Sweden
Research Site
Skoghall, , Sweden
Research Site
Skövde, , Sweden
Research Site
Skultuna, , Sweden
Research Site
Smedjebacken, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Stora Höga, , Sweden
Research Site
Sunnansjö, , Sweden
Research Site
Sunne, , Sweden
Research Site
Svärdsjö, , Sweden
Research Site
Trollhättan, , Sweden
Research Site
Upplands Vasby, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Vansbro, , Sweden
Research Site
Västerås, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hasvold LP, Bodegard J, Thuresson M, Stalhammar J, Hammar N, Sundstrom J, Russell D, Kjeldsen SE. Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients. J Hum Hypertens. 2014 Nov;28(11):663-9. doi: 10.1038/jhh.2014.43. Epub 2014 Jun 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CSE-ATA-2010/1
Identifier Type: -
Identifier Source: org_study_id